A method and system for identifying, sorting and collecting analytes, for example cells, in a sample fluid.
The present disclosure relates to a method and a microfluidic system platform to be used to characterize (identify), enumerate, classify, sort and extract/collect targeted particle/cell populations in suspension, e.g., rare cells circulating bodily fluids, such as blood. Although the present disclosure primarily focuses on circulating tumour cells (CTCs), it can also be used for any analyte or rare cell population, such as circulating endothelial cells (CECs), circulating melanoma cells (CMCs), circulating hybrid cells (CHCs), etc.
According to the WHO, cancer is the second leading cause of death worldwide, and caused around 10 million deaths in 2020. Globally, about 1 in 6 deaths is due to cancer. There were around 20 million new cancer cases globally in 2020 and this number is expected to reach around 30 million by 2040, causing 16 million deaths (Source: WHO IARC Globocan 2020).
Cancer is a deadly disease, however what kills is not the primary tumour but metastasis, which is spread of cancer. 90% of cancer related deaths are due to metastasis, therefore rapid identification of this process is critical for cancer treatment. CTCs are the most informant biomarkers for metastasis. They detach from the primary tumour and enter the bloodstream to eventually create a secondary tumour at another site. As they have the potential to stem for a new tumour formation in a separate tissue, their detection in blood is critical to assess the metastatic progression, to guide the therapy and to test and develop drugs. Early diagnosis of metastatic progression has uttermost importance to increase the survival rate and shorten the treatment period. In addition to diagnosis and prognosis, recurrence monitoring is also possible by detecting dormant CTCs in blood.
Real-time assessment of CTCs routinely in metastatic cancer patients in a non-invasive manner is crucial to assess the efficacy of therapy. Collection of CTCs is potentially possible via liquid biopsy, where a few mL of blood is drawn from the patient and traces of cancer are probed in the blood sample. Liquid biopsy is minimally invasive and brings many advantages over solid biopsy, where the tumour tissue is taken by surgery. However, retrieval of CTCs is a big challenge. In 1 mL of blood, there are billions of peripheral blood cells, where only 1-10 CTCs present. Their extreme rarity and inherent heterogeneity require sensitive, target specific and high throughput systems.
The present disclosure provides a technical solution for the above problem.
According to a first example of the disclosure, a method for characterizing analytes, for example cells, in a sample fluid is proposed, the method comprising passing a sample liquid containing analytes of at least a first type and analytes of a second type along a flow path through a fluid channel; analysing, in a first analysing unit including the fluid channel, the analytes of the at least first type and second type in the sample liquid, thereby obtaining first parameter values of at least one analyte characteristic associated with the analytes of the at least first type and second type; and storing, in a processing unit, the first parameter values of the at least one analyte characteristic.
An exemplary method further comprises altering a further analyte characteristic associated with the analyte of the first type compared to the further analyte characteristic associated with the analyte of the second type. The analytes of the at least first type and second type in the sample liquid may then be advantageously analysed in a second analysing unit including the fluid channel, thereby obtaining second parameter values of the at least one analyte characteristic associated with the analytes of the at least first type and second type.
An exemplary method further includes storing, in the processing unit, the second parameter values of the at least one analyte characteristic and characterizing, in the processing unit, the analytes of the first type from the analytes of the second type by comparing the second parameter values with the first parameter values.
This allows for an inline method capable of characterizing analytes from other analytes. In particular, very rare cells or analytes, mentioned in this application as analytes of a second type, may be herewith effectively identified from peripheral blood cells, mentioned in this application as analytes of a first type.
According to an example of the method of the disclosure altering the further analyte characteristic comprises the step of subjecting, in a device including the fluid channel, the analytes of the at least first type and second type in the sample liquid to an electric field.
In some embodiments, the method according to the disclosure, further comprises the step of separating in a separating unit mounted to the fluid channel, the analytes of the first type from the analytes of the second type based on the characterization in the processing unit and using the altered further analyte characteristic of the analyte of the first type. Accordingly, by separating the peripheral cells (analytes of the first type) from the sample fluid, the rare cells or analytes of the second type can also be efficiently separated and analysed for further research.
The step of separating the analytes of the first and second type may comprise applying an electric field to the sample fluid, and using the electric field to divert the analyte of the second type from the flow path. Additionally or alternatively, a valve can be used. The analyte of the second type can then be diverted from the flow path by guiding the flow to a desired outlet by changing the position of the valve. After separating the analytes of the first and second type, analytes of the second type may be collected in a collection reservoir.
Additionally, in a further example of the method according to the disclosure, it comprises the step of sorting the analytes of at least the first and second type on analyte size. This provides a prior selection of the analytes in the sample fluid further improving the efficiency and accuracy of the characterizing and separation steps of the method.
As the method according to the disclosure processes large amounts of data, the step of characterizing of the analytes of the first type from the analytes of the second type is preferably performed using one or more machine learning algorithms.
Additionally, one or more analysing steps of the method according to some embodiments of the present disclosure comprise electrical impedance spectroscopy (EIS), in particular multi-frequency electrical impedance spectroscopy.
According to an example of the present disclosure, the step of altering a further analyte characteristic comprises the step of altering a membrane or causing a mechanical cell deformation of an analyte and wherein the further analyte characteristic is the electrical impedance response of the analyte. In particular, if the altering step comprises charging outer membrane and/or electroporation, and the further analyte characteristic is the electrical properties of the analyte membrane, one of the analyte types can be effectively tagged for characterizing, in particular identification.
Methods according to the present disclosure may advantageously include the step of optically sensing a sensing region of the fluid channel.
According to another embodiment of the disclosure, a method for characterizing analytes, for example cells, in a sample fluid, is proposed that comprises performing the steps of any one or more of the foregoing methods according to the present disclosure, concurrently, in a plurality of different characterizing lines. The plurality of characterizing lines may receive analytes that have been sorted, for example, by size, during the initial step of sorting the analytes in the sample fluid to different of the plurality of the characterizing lines.
An example of a system for characterizing analytes, for example cells, in a sample fluid according to the disclosure includes at least one characterizing line, which line comprises at least a fluid channel defining a flow path having an inlet and an outlet and structured to allow a sample liquid containing analytes of at least a first type and analytes of a second type to pass through along the flow path. Between the inlet and the outlet seen in the direction of the flow path several units can be implemented, which perform process steps on the sample fluid, in particular on the analytes of the at least first and second type.
A first exemplary analysing unit includes the fluid channel and is structured to analyse the analytes of the at least first type and second type in the sample liquid and structured to obtain first parameter values of at least one analyte characteristic associated with the analytes of the at least first type and second type.
An altering unit also includes the fluid channel and may be located downstream from the first analysing unit structured for altering a further analyte characteristic associated with the analyte of the first type compared to the further analyte characteristic associated with the analyte of the second type. In an embodiment, the altering unit comprises an electric field generating unit, structured to subject the analytes of the at least first type and second type in the sample liquid to an electric field, thereby altering the further analyte characteristic associated with the analyte of the first type compared to the further analyte characteristic associated with the analyte of the second type. In particular, the altering unit may be structured for altering a membrane or causing a mechanical cell deformation of an analyte and wherein the further analyte characteristic is an electrical impedance response.
A second analysing unit including the fluid channel may be provided downstream from the altering unit. The second analysing unit is structured to analyse the analytes of the at least first type and second type in the sample liquid and is structured to obtain second parameter values of the at least one analyte characteristic associated with the analytes of the at least first type and second type.
The large amounts of data are processed by a processing unit, which is structured to acquire and store the first parameter values and second parameter values from the first and second analysing unit and to characterize the analytes of the first type from the analytes of the second type by comparing the second parameter values with the first parameter values.
This allows for an inline method capable of characterizing analytes from other analytes. In particular, very rare cells or analytes, mentioned in this application as analytes of a second type, are herewith effectively identified from peripheral blood cells, mentioned in this application as analytes of a first type.
Additionally, in an example of the system according to the disclosure, it comprises a separating unit including the fluid channel downstream from the second analysing unit. The separating unit is structured to separate the analytes of the first type from the analytes of the second type using the altered further analyte characteristic of the analyte of the first type, based on characterization signals generated and output by the processing unit.
By separating the analytes of the first type from the sample fluid, the analytes of the second type can also be efficiently separated and collected. For instance, the separating unit can comprise an electric field generating unit structured to apply an electric field to the sample fluid when it receives an activation signal from the processing unit for diverting the analyte of the second type from the flow path for its collection. Accordingly, exemplary embodiments of the system may include one or more collection unts, e.g., for collecting analytes of the second type. Some exemplary separating units may comprise a valve unit structured to divert the analyte of the second type from the flow path.
To further improve the efficiency and accuracy of the characterizing and separation of the several types of analytes, a prior sorting of the analytes in the sample fluid is obtained by implementing a sorting unit, which is including the fluid channel upstream from the first analysing unit and which is structured to sort the analytes of at least the first and second type on analyte size without making any selection.
An improved processing of the large amounts of data is achieved, as in a further beneficial example, the processing unit implements one or more machine learning algorithms for characterizing the analytes of the first type from the analytes of the second type.
Preferably, the first and second analysing unit comprise electrical impedance spectroscopy (EIS) means, in particular multi-frequency electrical impedance spectroscopy means, and furthermore the microfluidic device can be structured to charge and/or electroporate the membrane of the analyte of the first type.
Exemplary embodiments of the present disclosure may also include an optic sensing unit structured to optically sense a sensing region of the fluid channel.
Another embodiment of the present disclosure is a platform for characterizing analytes, for example cells, in a sample fluid, concurrently in a plurality of systems according to embodiments of the present disclosure. The platform comprises a plurality of characterizing lines associated with a plurality of systems, each system structured for characterizing analytes, for example cells, in a sample fluid. Such exemplary embodiments may further include a sorting device disposed upstream of the plurality of the systems and structured to sort analytes in the sample fluid to different characterizing lines of the plurality of systems.
The invention will now be discussed with reference to the drawings, which show in:
For a proper understanding of the disclosure, in the detailed description below corresponding elements or parts of the disclosure will be denoted with identical reference numerals in the drawings.
The technology according to the disclosure is designed for tumour cell detection, enumeration, purification, and collection. The design is formed of a versatile micro-electro-fluidic system (MEFS) that is based on fast and sensitive electrical impedance measurements with the option of coupling to optics for expanding the capabilities, such as real-time characterization. A technique and device for real-time characterization is described in applicant's other PCT application, filed concurrently with the present application, which other PCT application claims priority to the Dutch application no. 2030787 titled “A microfluidic device for detecting and characterizing at least one analyte, for example a cell, in a sample fluid.” filed on 31 Jan. 2022, the disclosure of which is incorporated by reference herein.
After their identification, preferably concurrently, in two or more of sensor 1, . . . , sensor n, analytes of a second type, such as rare cells, are separated from sensor 2, analytes of the first type, in the two or more fluid channels 1, 2, . . . , n, and steered to the two or more collection reservoirs 1, 2, . . . , n. Analytes of the first type, such as peripheral blood cells, are sent to waste.
The exemplary branch/characterizing line 10b is composed around a fluid channel 19b defining a flow path having an inlet 19b-1 and an outlet 19b-2. The fluid channel 19b structured to allow a sample liquid containing analytes of at least a first type 20-1 and analytes of a second type 20-2 to pass from the sorting unit 18 along the flow path between the inlet 19b-1 towards the outlet 19b-2. Illustrations of the different cell types in channel branches 10a, 10b, and 10c are representative, analytes of any type can be sorted into 10a or 10b or 10c based on their size. Analytes of first or second or any type may fall into the same size range and then co-exist in the same channel branch (10a, 10b or 10c). Therefore, the operation of the size-based pre-sorting unit 18 is independent of the analyte type, but is dependent on the analyte size.
There are three subunits 11, 12, and 13 that are being operated sequentially within one exemplary embodiment of the system: sub-unit 11 (first analysing unit) includes a detector or sensor unit and serves to detect a characteristic of one or more analytes, such as the size, membrane properties, cytoplasm properties, nucleus properties, and genomic content or nucleic acids and sending the information to the processing unit 14. Sub-unit 12 (an alteration unit) is structured to alter a characteristic of an analyte, such as the membrane, of WBCs, for example, by charging or electroporating the outer (plasma) membrane of WBCs, while leaving the outer (plasma) membrane of CTCs intact. Sub-unit 13 (second analysing unit) includes a detector or a sensor unit, which may be the same as sub-unit 11, and serves to detect a characteristic of one or more analytes, such as the same properties as sub-unit 11, and identify the shift in the signal due to an altered analyte characteristic, e.g., for WBCs caused by altered membrane, in the sub-unit 12. Sub-unit 13 subsequently sends the signal to the processing unit 14 for tagging WBCs at sub-unit 13. The data that detection and enumeration unit generates are processed by the processing unit 14 using machine learning algorithms for identification of each cell type (analyte of at least the first and second type) and this information is used to activate the valve 15a in the purification device 15 (sorting unit 15) to sort and collect tumour cells (analytes of the second type 20-2) in the collection chamber (reservoir) 16 or discard the rest of the cells (analytes of the first type 20-1) via waste outlet 17 (stage III).
The working principle of the method and system according to the disclosure as outlined in
The proposed system aims to detect and combine the known physical differences between tumour cells (e.g. denoted as analytes of the second type 20-2) and peripheral blood cells (accordingly denoted as analytes of the first type 20-1).
The second property (a second analyte characteristic) is the cytoplasmic content, such as the nuclear-to-cytoplasmic (N/C) ratio, cytoplasmic conductivity, cytoplasm composition or genomic content. Tumour cells typically represent higher N/C ratio (n1/c1) compared to white blood cells (n2/c2). This property can be derived by measuring the cells at a certain frequency range (section (2) in the graph on the right of
To further increase the specificity of the measurements, the membrane of white blood cells is altered, yielding a shift in its electrical impedance response, this is the further analyte characteristic used for the tagging or characterizing steps. This allows tagging white blood cells for their accurate identification.
Typically before any liquid biopsy application, blood sample is diluted in red blood cell (RBC) lysis buffer for eliminating RBCs from the solution to increase the signal-to-noise ratio as RBCs outnumber any other cell population in blood. This process also affects the (electrical) properties of the outer membrane of white blood cells, while their viability is preserved.
RBC lysis buffer alters the properties of the membrane of white blood cells by causing reversible pore formation (as in electroporation) on the membrane of white blood cells, hence creating a shift in its electrical response. Therefore, immersing in RBC lysis buffer can be used as an alternative to electrical charging or electroporation of cell membranes.
As an alternative to electroporation or immersing in RBC lysis buffer, mechanical alternation of white blood cells can also be performed. As an example, cells can be flown through converging-diverging channels for mechanical alteration, such as nucleus relocation, which causes a shift in electrical response, too. Difference in deformability levels between tumour cells and white blood cells results in a differences in their electrical impedance response.
The change in the electrical response of white blood cells is measured after being immersed in a RBC lysis buffer. After the measurement it was validated that tumour cells remain intact and their electrical impedance response does not change.
To have a better control over the process and to further increase the specificity, an electrical alteration of the outer (plasma) membrane of the white blood cells can be applied. Since the system according to the disclosure may be equipped with 3D electrodes, for example, those described in connection with and illustrated in
Being able to perform electroporation of cells with high level of control allows other applications, such as enhanced (content/drug) delivery into cells/organisms. One striking example would be the controlled electroporation of cells for genomic delivery for bioproduction. Without the requirement for purification after the treatment, this technology would replace the expensive chemical techniques, which also produce by-products, where e.g. bioburden becomes an issue and purification becomes a necessity. Moreover, online monitoring of the efficiency of delivery and the process of replication of nucleic acids is possible by coupling electrical sensing to electroporation. This can be applied to any cell or organism with an outer membrane (e.g., mammalian cells) and/or a wall (e.g., bacteria, yeast cells).
The disclosure allows for the analysis at single cell level and prevents that any cell (analyte) from being discarded or sent to the waste before being fully inspected. Presently known prior art systems provide only blind separation routines based on a specific target property by processing bulk volumes. Different from the existing solutions, this disclosure implements a sensor unit instead of a blind partitioning approach and enables an active decision making approach by this sensor unit for the collection of tumour cells or any target group/analytes within the sample. The detection and isolation of tumour cells as outlined in this disclosure are optionally label-free, which allow further downstream analysis, such as assessment of drug response for guiding the treatment or molecular analysis for drug development as the cells remain intact. The platform according to the disclosure will allow the utilization of such analyses on-the-go and in real-time with the coupling optical sensors or utilizing integrated optics into the device, for example, as described with reference to
With the use of artificial intelligence (AI) and/or machine/deep learning techniques, the decision making as to the detection and isolation of tumour cells can already be implemented at the device level by integrating microprocessor for replacing a computer. Accordingly, the device platform and method according to the disclosure are versatile as the sensors being used can be tuned, activated, or deactivated depending on the desired application mode.
The system only requires dilution of blood samples as sample preparation. Therefore, total analysis times will be very short, and the costs will be low compared to most of the state-of-the-art systems that provide many antibody-based and/or multi-step approaches.
To further expand the capabilities of the system (e.g. on-the-fly characterization of cells), optical detection can be combined. One example of the disclosure comprises an optic sensing unit structured to optically sense a sensing area of the fluid channel, preferably, between the at least one pair of electrodes. This enables a system capable of electrical and optical detection of analytes, such as particles or cells in an electrolyte solution. For example, a full spectrum optical spectrometer and a high-speed camera as well as integrated optical waveguides can be used for collecting the optical data for label-free and/or fluorescent measurements. Fast optical data via the spectrometer is provided and on-demand imaging can be performed via high-speed CMOS cameras for visualization of the events of interest for end user.
The microfluidic device 100 may include a first substrate 130a and a second substrate 130b. Materials suitable for making the one or more substrates 130a-130b include transparent materials, which are preferably compatible with microfabrication and thin-film processing techniques. Examples may include glass and silica. At least a portion of a wall of the fluid channel 110 may be formed by a first recess 131a in the first substrate 130a. Additionally or alternatively, at least a portion of the wall of the fluid channel 110 may be formed by a second recess 131b in the second substrate 130b. Preferably, the first recess 131a has the same shape as the second recess 131b, which greatly simplifies the manufacturing of the microfluidic devices. Most preferably, the first and second recesses 131a-131b are symmetric with respect to the mid- or central plane 160c (shown in
The electrodes 120a-120b can be placed facing each other at different, preferably opposite, sides of the fluid channel 110. The first electrode 120a may be placed in the recess 131a of the first substrate 130a, and the second electrode 120b may be placed in the recess 131b of the second substrate 130b. Alternatively, one or more three-dimensional curved electrodes of the present disclosure, such as the electrodes 120a-120b, may be placed at another chosen location, such that the electrodes face each other and otherwise in accordance with the principles of the present disclosure. Examples of the processes that can be used to place the electrodes include, without limitation, evaporation, sputtering, or direct printing of metals. In the present disclosure, the term “placed” shall be interpreted to include within its meaning any type of depositing, arranging, mounting, integrating, or otherwise providing the one or more electrodes in any other manner consistent with the present disclosure.
Reference numeral 140 schematically depicts a known configuration of an electric field generating unit, which is connected with both electrodes 120a-120b and which is capable of applying an electric field distribution in the channel 110 between both electrodes 120a-120b. The electric field distribution in the fluid channel 110 between both electrodes 120a-120b is shown by the schematic electric field lines 141.
The microfluidic device 100 according to the disclosure may further include an optic sensing unit 150 arranged to optically detect or sense a region of the fluid channel 110 between the at least one pair of the first and second electrodes 120a and 120b. The optic sensing/detecting unit 150 can be structured as or include an optical waveguide, a laser device, and/or an optical sensor. In another beneficial example, the optical sensor can be a charge-coupled device (CCD), CMOS device, etc. In an embodiment of the present disclosure, optical measurements using an optic sensing unit 150 are performed concurrently, and preferably synchronously, with the electrical measurements, e.g., using electrodes 120a and 120b. Since the electrodes 120a-120b are disposed over only a portion of an inner surface wall 110′ of the fluid channel 110, they do not obstruct or hinder the optical sensing axis 150a of the optic sensing unit 150. Therefore, label-free (LED illumination, multi-focus or multi-depth arrangement, transmitted or reflected light, lens-free imaging, waveguide integration, PMT integration, etc.) or fluorescent (using specific biomarkers for staining) measurements are possible. In one exemplary microfluidic device 100, the optical sensing axis 150a may be perpendicular to the flow direction through the fluid channel 110, but in other exemplary embodiments it can be horizontal. In general, the optical sensing axis 150a may form any angle with the direction of the flow through the fluid channel 110 that allows for optical measurements to be made through the portion(s) of the first and or second substrate(s) 130a and 130b that are not obstructed by the electrode(s) 120a and 120b.
The manufacturing process and material options can be the same as those described in connection with the previous configuration, shown in
As an alternative to integrated waveguides, far field optics can be used for this configuration. The optical components, such as light sources focusing the light and image sensors for collecting and sensing the scattered light can be placed at the top and bottom of the device externally (outside). The waveguide units 160a and 160b of both examples 100′ and 100″ of
In a first example, illustrated in
In a second example, as illustrated in
Exemplary microfluidic devices described above may be advantageously included in exemplary altering units to perform charging of or reversible electroporation of subject analytes. Thus, in addition to being used as a sensor, some embodiments of the microfluidic device can be used for altering, such as electrical treatment and manipulation of analytes, such as cells and particles in suspension. The ability of controlling the electrode area that is in contact with the electrolyte by defining the coverage angle of the concave electrodes provides high level of control on the parameters that are applied for electrical treatment and manipulation. Alteration or treatment of particles or cells can be but is not limited to electroporation of cells for content delivery or extraction of inner cell content after e.g., bioproduction. Pore formation during electroporation can be reversible or irreversible as this process (electrode area, applied voltage, etc.) is well controlled and efficient with the proposed configuration. Alteration or manipulation of particles or cells can be but is not limited to guiding them by creating dielectrophoretic forces on these particles/cells. These forces can be generated by targeting a specific property, such as size, morphology, or phenotype, and by adjusting the frequency and the amplitude of the excitation voltage based on the selected property. Dielectrophoretic force then can be used to steer or direct the particles or cells in flow, or collect/concentrate them on defined areas in the device for follow-up downstream analyses.
The additional optical data obtained with the optic sensing unit provide information on physical properties, such as inner and outer morphology, size, shape, and phenotype. By combining these electric and optical data sets, the systems and methods according to the disclosure can be used as a flow cytometer for detection, enumeration, characterization, and/or classification of target analytes or target particles in a suspension, such as biological cells in blood. The systems and methods according to the disclosure can also be used as a hematology analyzer for blood cell classification and counting.
The processing unit 14 implements machine/deep learning algorithms for dealing with the large amount of data that is collected by various measurement channels. The readings gathered from the sensors are processed and a decision is made to steer tumour cells to collection reservoirs downstream of detection zone using on/off valves (dielectrophoretic, magnetic, pinched, etc.).
For the dielectrophoretic valve (
For the two-way valve 150a in
High-throughput requirements can be met by multiplexing the analysing units by utilizing modular size-based pre-sorting units, which will also be responsible for removal of the excessive carrier liquid. This approach will not only enable reaching the required throughput levels but also significantly increase the signal-to-noise ratio as the measurement volumes match with the size of the pre-sorted cells.
Combining these elements, the present disclosure will offer the first tumour cell analysis system that is able to purify and collect tumour cells without losing a single cell. Intact and viable tumour cells will be ready for downstream analysis. On-line enumeration, and digital and automated operation of the system are the key advantages.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2030788 | Jan 2022 | NL | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/NL2023/050039 | 1/31/2023 | WO |